The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Evidence-based pharmacological treatment of generalized anxiety disorder
Open accessAbstract
Generalized anxiety disorder (GAD) is common in community and clinical settings. The associated individual and societal burden is substantial, but many of those who could benefit from treatment are not recognized or treated. This paper reviews the pharmacological treatment of GAD, based on findings of randomized placebo-controlled studies. Particular attention is paid to response rates to acute treatment, treatment tolerability, prediction of response, duration of treatment, and further management of patients who do not respond to initial treatment approaches. On the basis of their proven efficacy and reasonable tolerability in randomized placebo-controlled trials, recent evidence-based guidelines for pharmacological management have recommended initial treatment with either a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor, although there is also good evidence for the efficacy of pregabalin and quetiapine. It is difficult to predict reliably which patients will respond well to pharmacological treatment, but response to antidepressants is unlikely if there is no evidence of an onset of effect within 4 wk. The small number of placebo-controlled relapse-prevention studies causes uncertainty about the optimal duration of treatment after a satisfactory initial response, but continuing treatment for at least 12 months is recommended. There have been few investigations of the further management of patients who have not responded to first-line treatment, but switching to another evidence-based treatment, or augmentation approaches may be beneficial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503 · cited 2×
“A review of epidemiological studies in Europe suggests a 12-month prevalence of 1.2–1.9%, and a lifetime prevalence of 4.3–5.9% (Wittchen & Jacobi, 2005).”
BackgroundInfluentialBruce, S. E., Yonkers, K. A., Otto, M. W., Eisen, J. L., Weisberg, R. B., Pagano, M., Shea, M. T., & Keller, M. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1179 · Cited by 963
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 2×
“…beyond initial response substantially reduces the risk of early relapse and later recurrence of symptoms in patients with unipolar depressive disorder (Geddes et al. 2003), but the value of long-term treatment in GAD is less well established, due to the smaller number of relapse-prevention studies.”
BackgroundNitschke, J. B., Sarinopoulos, I., Oathes, D. J., Johnstone, T., Whalen, P. J., Davidson, R. J., & Kalin, N. H. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07101682 · Cited by 375
Wittchen, H.-U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00002 · Cited by 299
Carney, C. E., Segal, Z. V., Edinger, J. D., & Krystal, A. D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0211 · Cited by 265 · cited 1×
“SSRIs and related drugs may have only limited benefit, or even deleterious effects, on sleep disturbance, despite beneficial effects on other depressive and anxiety symptoms (Carney et al. 2007 ; Cervena et al. 2005).”
BackgroundJudd, L. L., Kessler, R. C., PauIus, M. P., Zeller, P. V., Wittchen, H. ‐., & Kunovac, J. L. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05960.x · Cited by 222
Internalizing Behaviors in 4-Year-Old Children Exposed in Utero to Psychotropic Medications
Misri, S., Reebye, P., Kendrick, K., Carter, D., Ryan, D., Grunau, R. E., & Oberlander, T. F. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.6.1026 · Cited by 207
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Self-citation
Cited by
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Self-citationThe GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
Physical activity and anxiety: A perspective from the World Health Survey
Stubbs, B., Koyanagi, A., Hallgren, M., Firth, J., Richards, J., Schuch, F., Rosenbaum, S., Mugisha, J., Veronese, N., Lahti, J., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.028 · Cited by 324
Moving to Beat Anxiety: Epidemiology and Therapeutic Issues with Physical Activity for Anxiety
Kandola, A., Vancampfort, D., Herring, M., Rebar, A., Hallgren, M., Firth, J., & Stubbs, B. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0923-x · Cited by 291
Metadata
- Authors
- Baldwin, D. S., Waldman, S., & Allgulander, C.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-07
- Volume
- 14
- Issue
- 05
- Pages
- 697-710
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2141232381
- Cited by
- 168
- References
- 19
- FWCI
- 18.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence-based pharmacological treatment of generalized anxiety disorder. https://app.cochat.ai/papers/10.1017/s1461145710001434
- The paper
- Baldwin, D. S., Waldman, S., & Allgulander, C. (2011). Evidence-based pharmacological treatment of generalized anxiety disorder. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145710001434
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.